Pricing:

Single User Licence
$4200
Multi User License Upto 5 Users
$6500
Enterprise License
$8400
Download Sample Add to Cart Buy Now

Don’t see what you are Looking For:

We can create a custom report for you, please fill the form below

Download Free Sample Now

Global Influenza Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Test Type;

Traditional Diagnostic Test and Molecular Diagnostic Assay

By Product;

Point-Of-Care Testing, Immunodiagnostics, and Molecular Diagnostics

By End-Use;

Research Laboratory, Hospitals, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)

Report ID: Rn266240959 Published Date: May, 2025 Updated Date: June, 2025

Download Free Sample Now Request Customized Sample

Influenza Testing Market Overview

Influenza Testing Market (USD Million)

Influenza Testing Market was valued at USD 1,809.20 million in the year 2024. The size of this market is expected to increase to USD 2,982.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.

Global Influenza Testing Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 7.4 %

Study Period	2025 - 2031
Base Year	2024
CAGR (%)	7.4 %
Market Size (2024)	USD 1,809.20 Million
Market Size (2031)	USD 2,982.07 Million
Market Concentration	Medium
Report Pages	331

1,809.20

2024

2,982.07

2031

Major Players

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Quidel Corporation
Becton, Dickinson and Company (BD)
bioMérieux SA
DiaSorin S.p.A.
Luminex Corporation
Meridian Bioscience, Inc.
Sekisui Diagnostics, LLC
Thermo Fisher Scientific Inc.
Cepheid
GenMark Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
Corgenix Medical Corporation
Hologic, Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Influenza Testing Market

Fragmented - Highly competitive market without dominant players

Influenza remains a widespread viral infection, prompting a continual rise in the demand for timely and accurate diagnostic tools. Due to recurring seasonal outbreaks and the threat of evolving flu strains, healthcare systems are prioritizing efficient testing solutions. Each year, influenza affects approximately 5% to 10% of adults and 20% to 30% of children, highlighting the vital role of early diagnosis in controlling transmission and improving clinical outcomes.

Rising Preference for Point-of-Care Testing
There has been a noticeable shift toward point-of-care testing (POCT) for influenza, driven by the need for rapid and convenient diagnostic processes. POCT methods have become increasingly favored for their speed and efficiency, with over 60% of healthcare providers adopting them in place of conventional laboratory diagnostics. These systems not only shorten the diagnostic timeline but also enhance real-time decision-making in treatment settings.

Technological Advancements Enhancing Test Accuracy
The influenza testing market is experiencing significant growth due to advances in molecular diagnostics. Technologies such as nucleic acid amplification and AI-supported result interpretation are improving test precision. These innovations have led to an estimated 25% rise in the adoption of diagnostic solutions, as healthcare providers seek tools that deliver higher sensitivity and reliability.

Public Health Initiatives Bolstering Testing Uptake
Widespread health campaigns and government-led screening programs are strengthening awareness around influenza testing. These initiatives aim to reduce disease burden through timely detection and ongoing surveillance. As a result, hospitals, diagnostic centers, and retail clinics are witnessing a steady increase in testing volumes, backed by stronger public participation.

Influenza Testing Market Recent Developments

In June 2022, BD (Becton, Dickinson, and Company) introduced the BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic test designed to detect SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV) using a single nasal or nasopharyngeal swab. The test received CE marking, confirming its compliance with European health and safety standards. By offering a comprehensive solution for identifying multiple respiratory infections from a single sample, this launch was aimed at strengthening BD’s product portfolio and expanding its market presence. It also positioned the company to capitalize on increasing diagnostic demands and boost overall business revenue.
In February 2019, Abbott launched its reformulated rapid influenza diagnostic test, BinaxNOW Influenza A & B Card 2, which received approval from the U.S. Food and Drug Administration (FDA). The test is designed for use with Abbott’s DIGIVAL diagnostic reader, enabling the quick and accurate detection of influenza viruses. This launch strengthened Abbott’s presence in the respiratory diagnostics space by enhancing its product portfolio and supporting its goal to reach a wider customer base through improved point-of-care solutions.

Influenza Testing Market Segment Analysis

In this report, the Influenza Testing Market has been segmented by Test Type, Product, End-use, and Geography.

Influenza Testing Market, Segmentation by Test Type

The Influenza Testing Market has been segmented by Test Type into Traditional diagnostic test and Molecular diagnostic assay.

Traditional Diagnostic Test

Traditional diagnostic tests, including Rapid Influenza Diagnostic Tests (RIDTs), viral cultures, and immunofluorescence assays, are commonly used for detecting influenza. These methods deliver quick results, typically within 15 to 30 minutes, but they often have lower sensitivity, which can lead to false-negative outcomes. Despite the growing popularity of molecular diagnostics, traditional tests still hold a market share of around 45%. However, their use is gradually decreasing as more accurate, quicker alternatives emerge in the market.

Molecular Diagnostic Assay

Molecular diagnostic assays, such as PCR (Polymerase Chain Reaction) tests, have become a preferred choice due to their high sensitivity and accuracy in detecting influenza viruses. These tests can identify viral RNA even in small quantities, ensuring more reliable results, particularly in patients with low viral loads. Representing approximately 55% of the influenza testing market, molecular diagnostics are increasingly favored for their quick turnaround and precision, making them essential in clinical settings, especially among high-risk groups.

Influenza Testing Market, Segmentation by Product

The Influenza Testing Market has been segmented by Product into Point-Of-Care Testing, Immunodiagnostics, and Molecular Diagnostics.

Point-Of-Care Testing

Point-of-care testing (POCT) has significantly impacted the influenza testing market by enabling fast, on-site diagnostics. This testing method is widely used in various healthcare settings such as clinics, hospitals, and even home environments. POCT devices deliver rapid results, often within minutes, making them essential during flu outbreaks or peak seasons. The point-of-care segment holds about 30% of the influenza testing market. Its growing popularity is driven by the increasing need for accessible and immediate testing options that improve patient care and streamline the diagnostic process.

Immunodiagnostics

Immunodiagnostics is a vital segment within the influenza testing market, relying on antigen or antibody-based tests to identify the presence of influenza. These diagnostic tools are cost-effective and easy to use, offering reliable results in a short time frame. Immunodiagnostics are commonly used to detect active infections or previous exposures to the virus, making them crucial in both clinical and laboratory settings. Representing approximately 25% of the market, immunodiagnostic tests continue to be a popular choice due to their affordability and efficiency in providing essential diagnostic information.

Molecular Diagnostics

Molecular diagnostics, including PCR (Polymerase Chain Reaction) and other nucleic acid-based tests, are considered the most accurate and sensitive influenza testing methods. These tests are capable of detecting even small quantities of viral genetic material, making them indispensable for identifying infections in patients with low viral loads or those who are asymptomatic. Molecular diagnostics dominate the influenza testing market, accounting for about 45% of the overall market share. Their high accuracy and reliability are fueling their widespread adoption, particularly as healthcare providers increasingly rely on advanced diagnostic technologies to ensure timely and precise influenza detection.

Influenza Testing Market, Segmentation by End-use

The Influenza Testing Market has been segmented by End-use into Research laboratory, Hospitals and Others.

Research Laboratory

Research laboratories play a crucial role in the influenza testing market by conducting detailed studies and experiments to understand the virus’s behavior, mutations, and transmission patterns. These labs are equipped with advanced diagnostic tools, such as PCR tests, to ensure high levels of accuracy. Research labs contribute to around 40% of the overall market share, as their work drives innovations in influenza diagnostics and vaccine development.

Hospitals

Hospitals are major contributors to the influenza testing market, where timely and accurate diagnosis is essential for patient care. Influenza testing is routinely conducted in emergency departments, intensive care units, and outpatient clinics to determine the course of treatment. The hospital segment accounts for approximately 50% of the influenza testing market, with hospitals being the primary site for widespread testing, particularly during flu seasons.

Others

The Others category in the influenza testing market includes clinics, private diagnostic labs, and home testing solutions. This segment accounts for the remaining 10% of the market share. As home testing kits become more accessible and healthcare services diversify, this segment is expected to grow in importance, offering consumers more convenient testing options outside traditional medical settings.

Influenza Testing Market, Segmentation by Geography

In this report, the Influenza Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Regions and Countries Analyzed in this Report

Legend

North America

Rest of North America

Europe

Rest of Europe

Asia Pacific

Rest of Asia Pacific

Middle East and Africa

Rest of Middle East and Africa

Latin America

Rest of Latin America

Rest of the World

Influenza Testing Market Share (%), by Geographical Region, 2024

North America

North America holds a dominant position in the influenza testing market, accounting for approximately 35% of the total market share. The region benefits from advanced healthcare infrastructure, high demand for rapid and accurate diagnostic tools, and a robust healthcare system. The ongoing research and development efforts in molecular diagnostics and point-of-care testing contribute to the region's leadership in the global market.

Europe

Europe is a significant player in the influenza testing market, contributing to nearly 25% of the overall market share. The region has a well-established healthcare system that promotes the adoption of advanced diagnostic technologies. Countries in Europe also emphasize preventive healthcare measures, leading to higher demand for reliable influenza testing solutions, especially during seasonal flu outbreaks.

Asia Pacific

Asia Pacific is witnessing rapid growth in the influenza testing market, with a market share of around 20%. The region's expanding healthcare infrastructure, along with increasing awareness about influenza prevention and diagnostics, is driving the growth of this segment. Countries such as China and India are expected to experience substantial market expansion due to large populations and improving access to healthcare.

Middle East and Africa

The Middle East and Africa region contributes about 10% to the influenza testing market. The demand for influenza diagnostics in this region is primarily driven by the growing healthcare sector and increasing government efforts to combat infectious diseases. However, the market growth is somewhat limited by economic challenges and accessibility issues in some countries.

Latin America

Latin America holds around 10% of the influenza testing market. The region is witnessing steady growth due to increased investments in healthcare infrastructure and better access to diagnostic tools. Countries like Brazil and Mexico are leading the market in the adoption of advanced influenza testing solutions, although economic constraints still pose challenges to broader market expansion.

Influenza Testing Market Trends

This report provides an in depth analysis of various factors that impact the dynamics of Influenza Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis

Comprehensive Market Impact Matrix

This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.

Market Forces ↓ / Impact Areas →	Market Growth Rate	Competitive Landscape	Customer Behavior	Regulatory Influence	Innovation Potential
Drivers	High impact (e.g., tech adoption, rising demand)	Encourages new entrants and fosters expansion	Increases usage and enhances demand elasticity	Often aligns with progressive policy trends	Fuels R&D initiatives and product development
Restraints	Slows growth (e.g., high costs, supply chain issues)	Raises entry barriers and may drive market consolidation	Deters consumption due to friction or low awareness	Introduces compliance hurdles and regulatory risks	Limits innovation appetite and risk tolerance
Opportunities	Unlocks new segments or untapped geographies	Creates white space for innovation and M&A	Opens new use cases and shifts consumer preferences	Policy shifts may offer strategic advantages	Sparks disruptive innovation and strategic alliances

Drivers, Restraints and Opportunity Analysis

Drivers:

Surge in seasonal influenza outbreaks
Demand for early diagnostic solutions
Advancements in rapid testing technologies
Growth in point-of-care testing - The rising adoption of point-of-care testing (POCT) is a major catalyst for the growth of the influenza testing market. POCT offers the advantage of delivering rapid diagnostic results directly at the patient’s location, eliminating the delay associated with centralized laboratory testing. This is especially crucial in settings like emergency departments, outpatient clinics, and rural healthcare centers, where immediate diagnosis can lead to timely treatment initiation and effective infection control. Early detection through POCT not only improves patient outcomes but also helps curb the transmission of the virus within communities.

Technological advancements have significantly enhanced the capabilities of POCT devices, making them more accurate, portable, and easy to use. The development of molecular-based point-of-care platforms has improved diagnostic precision, offering high sensitivity and specificity comparable to lab-based methods. These innovations are gaining widespread acceptance across healthcare systems globally, particularly in the context of heightened awareness around infectious disease outbreaks. As healthcare providers seek faster and more efficient tools to manage seasonal and pandemic influenza, the demand for POCT is expected to continue driving the market forward.

Restraints:

High cost of diagnostic equipment
Variability in test result accuracy
Limited access in rural areas
Stringent regulatory approval processes - Stringent regulatory approval processes continue to act as a major constraint on the expansion of the influenza testing market. Regulatory authorities such as the FDA, EMA, and other regional bodies require comprehensive clinical validation and strict adherence to safety and performance standards before any diagnostic product can be introduced for clinical use. These processes involve lengthy review cycles, complex documentation, and substantial financial investment, which collectively delay the launch of innovative testing solutions. While these measures ensure patient safety and product reliability, they also pose a barrier for rapid market entry.

For emerging diagnostic companies and smaller innovators, these regulatory demands can be particularly challenging. Even after securing approval, manufacturers are required to maintain ongoing compliance with post-market surveillance and quality control protocols. This continuous regulatory pressure can slow down the adoption of advanced diagnostic tools, especially during periods of high demand such as seasonal flu outbreaks or public health emergencies. As a result, the availability and accessibility of faster, more accurate influenza testing options may be restricted, ultimately hindering the overall responsiveness of healthcare systems to emerging infectious threats.

Opportunities:

Rise in home testing adoption
Integration with digital health platforms
Emerging multiplex diagnostic innovations
Expansion in telehealth-driven screening - The growing integration of telehealth-driven screening is creating substantial opportunities within the influenza testing market. The rapid expansion of telemedicine services has revolutionized how healthcare is delivered, allowing patients to receive timely evaluations without visiting clinical settings. This model is particularly effective for managing influenza, where early detection and isolation are critical to controlling transmission. By embedding screening protocols into virtual consultations, providers can accelerate testing referrals and enhance responsiveness during peak flu seasons or outbreaks.

Modern telehealth platforms increasingly support home-based diagnostic options, enabling patients to conduct influenza tests under remote supervision or with follow-up guidance from healthcare professionals. The convenience and speed of this approach help improve patient compliance while reducing the pressure on hospitals and urgent care centers. Coupled with digital symptom tracking tools and immediate medical advice, this model promotes faster diagnosis and timely antiviral treatment, ultimately improving patient outcomes.

The impact of telehealth is particularly significant in remote or underserved communities, where access to healthcare infrastructure remains limited. Through virtual care models, influenza screening can reach wider populations, promoting healthcare equity and timely intervention. This has driven demand for compact, reliable, and user-friendly diagnostic kits designed specifically for non-clinical use, expanding the commercial reach of influenza testing products.

As the digital health ecosystem continues to evolve, strategic partnerships between telehealth providers and diagnostic companies are expected to accelerate. These collaborations are facilitating the integration of rapid testing into virtual care workflows, enhancing accessibility and market penetration. The continued advancement of telemedicine represents a sustainable growth avenue, offering new pathways for delivering efficient and scalable influenza diagnostic solutions globally.

Influenza Testing Market Competitive Landscape Analysis

Key players in Influenza Testing Market include.

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Quidel Corporation
Becton, Dickinson and Company (BD)
bioMérieux SA
DiaSorin S.p.A.
Luminex Corporation
Meridian Bioscience, Inc.
Sekisui Diagnostics, LLC
Thermo Fisher Scientific Inc.
Cepheid
GenMark Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
Corgenix Medical Corporation
Hologic, Inc.

In this report, the profile of each market player provides following information:

Company Overview and Product Portfolio
Market Share Analysis
Key Developments
Financial Overview
Strategies
Company SWOT Analysis

Introduction
1. Research Objectives and Assumptions
2. Research Methodology
3. Abbreviations
Market Definition & Study Scope
Executive Summary
1. Market Snapshot, By Test Type
2. Market Snapshot, By Product
3. Market Snapshot, By End-use
4. Market Snapshot, By Region
Influenza Testing Market Dynamics
1. Drivers, Restraints and Opportunities
  1. Drivers
    1. Surge in seasonal influenza outbreaks
    2. Demand for early diagnostic solutions
    3. Advancements in rapid testing technologies
    4. Growth in point-of-care testing
  2. Restraints
    1. High cost of diagnostic equipment
    2. Variability in test result accuracy
    3. Limited access in rural areas
    4. Stringent regulatory approval processes
  3. Opportunities
    1. Rise in home testing adoption
    2. Integration with digital health platforms
    3. Emerging multiplex diagnostic innovations
    4. Expansion in telehealth-driven screening
2. PEST Analysis
  1. Political Analysis
  2. Economic Analysis
  3. Social Analysis
  4. Technological Analysis
3. Porter's Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitutes
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Segmentation
1. Influenza Testing Market, By Test Type, 2021 - 2031 (USD Million)
  1. Traditional Diagnostic Test
  2. Molecular Diagnostic Assay
2. Influenza Testing Market, By Product, 2021 - 2031 (USD Million)
  1. Point-Of-Care Testing
  2. Immunodiagnostics
  3. Molecular Diagnostics
3. Influenza Testing Market, By End-use, 2021 - 2031 (USD Million)
  1. Research Laboratory
  2. Hospitals
  3. Others
4. Influenza Testing Market, By Geography, 2021 - 2031 (USD Million)
  1. North America
    1. United States
    2. Canada
  2. Europe
    1. Germany
    2. United Kingdom
    3. France
    4. Italy
    5. Spain
    6. Nordic
    7. Benelux
    8. Rest of Europe
  3. Asia Pacific
    1. Japan
    2. China
    3. India
    4. Australia & New Zealand
    5. South Korea
    6. ASEAN (Association of South East Asian Countries)
    7. Rest of Asia Pacific
  4. Middle East & Africa
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
  5. Latin America
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
Competitive Landscape
1. Company Profiles
  1. F. Hoffmann-La Roche Ltd.
  2. Abbott Laboratories
  3. Quidel Corporation
  4. Becton, Dickinson and Company (BD)
  5. bioMérieux SA
  6. DiaSorin S.p.A.
  7. Luminex Corporation
  8. Meridian Bioscience, Inc.
  9. Sekisui Diagnostics, LLC
  10. Thermo Fisher Scientific Inc.
  11. Cepheid
  12. GenMark Diagnostics, Inc.
  13. Bio-Rad Laboratories, Inc.
  14. Corgenix Medical Corporation
  15. Hologic, Inc.
Analyst Views
Future Outlook of the Market